Journal of Ophthalmic and Vision Research
ISSN: 2008-322X
The latest research in clinical ophthalmology and vision science
Intensity-modulated Radiation Therapy in the Management of Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome
Published date: Jul 10 2025
Journal Title: Journal of Ophthalmic and Vision Research
Issue title: Volume 20 - 2025
Pages: 1 - 8
Authors:
Abstract:
Purpose: This study aimed to report the efficiency and safety of using intensity-modulated radiation therapy (IMRT) in treating diffuse choroidal hemangioma (DCH) in patients with Sturge- Weber syndrome (SWS).
Methods: IMRT planning was carried out for each case after patient fixation, CT simulation, and target delineation. The purpose of treatment planning was to deliver the prescribed dose of 20 Gy to at least 95% of the planning target volume (PTV). The primary follow-up goal was to evaluate the efficacy and safety of IMRT as an alternative to traditional 3D conformal radiotherapy methods. The case series involved patients with DCH and varying degrees of vision impairment who underwent IMRT.
Results: Five patients, comprising two men and three women, with an average age of 14.4 ± 3.78 years, were included in this study. These patients were followed up for an average duration of 14.4 ± 6.84 months. All patients exhibited notable reduction in subretinal fluid, significant tumor regression, and minimal side effects. Visual acuity improved in patients with pre-IMRT vision of hand motion or better.
Conclusion: The findings suggest that IMRT is a promising, low-complication treatment option for managing DCH in SWS patients, warranting further research and potential integration into clinical practice
Keywords: Diffuse Choroidal Hemangioma, Intensity-modulated Radiotherapy, Sturge-Weber Syndrome
References:
1. Formisano M, di Pippo MC, Scuderi L, Abdolrahimzadeh S. Current concepts on diffuse choroidal hemangioma in Sturge Weber syndrome. Ophthalmic Genet 2021;42:375–382.
2. Sánchez-Espino LF, Ivars M, Antoñanzas J, Baselga E. Sturge-Weber Syndrome: A review of pathophysiology, genetics, clinical features, and current management approach. Appl Clin Genet 2023;16:63–81.
3. Hassanpour K, Nourinia R, Gerami E, Mahmoudi G, Esfandiari H. Ocular manifestations of the Sturge-Weber Syndrome. J Ophthalmic Vis Res 2021;16:415–431.
4. Helmi HA, Alkatan HM, Al-Essa RS, Aljudi TW, Maktabi AMY, Eberhart CG. Choroidal hemangioma in Sturge- Weber Syndrome: Case series with confirmed tissue diagnosis. Int J Surg Case Rep 2021;89:106626.
5. Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of choroidal hemangioma in Sturge-Weber Syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011;56:68–85.
6. Kubicka-Trząska A, Kobylarz J, Romanowska-Dixon B. Ruthenium-106 plaque therapy for diffuse choroidal hemangioma in Sturge-Weber Syndrome. Case Rep Ophthalmol Med 2011;2011:785686.
7. Hwang J, Yu J. MON-077: A case of growth hormone deficiency in Sturge-Weber Syndrome. J Endocr Soc 2020;4:MON-077.
8. Chaitanya A, Sruthimag G, Mds GP. Cryo-surgical management of angiomatous gingival overgrowth associated with Sturge-Weber Syndrome (SWS): A case report. IJSR 2020;IX:9.
9. McDonald TL, Hung AY, Thomas CR, Wood LJ. Localized External Beam Radiation Therapy (EBRT) to the pelvis induces systemic IL-1beta and TNF-alpha production: Role of the TNF-alpha signaling in EBRT-induced fatigue. Radiat Res 2016;185:4–12.
10. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. IJROBP 2001;51:880–914.
11. Taylor A, Powell ME. Intensity-modulated radiotherapy– What is it? Cancer Imaging 2004;4:68–73.
12. Staffurth J; Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010;22:643–657.
13. Hong TS, Ritter MA, Tomé WA, Harari PM. Intensitymodulated radiation therapy: Emerging cancer treatment technology. Br J Cancer 2005;92:1819–1824.
14. Randon M, Lévy-Gabriel C, Abbas R, Dendale R, Lumbroso L, Desjardins L, et al. Results of external beam radiotherapy for diffuse choroidal hemangiomas in Sturge-Weber Syndrome. Eye (Lond) 2018;32:1067–1073.
15. Schilling H, Sauerwein W, Lommatzsch A, Friedrichs W, Brylak S, Bornfeld N, et al. Long-term results after low dose ocular irradiation for choroidal haemangiomas. Br J Ophthalmol 1997;81:267–273.
16. Li J, Jin EZ, Liang JH. High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: A retrospective study of 25 Chinese patients. Int J Ophthalmol 2020;13:425–430.
17. Shields CL, Honavar SG, Shields JA, Cater J, Demirci H. Circumscribed choroidal hemangioma: Clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001;108:2237–2248.
18. Elizalde J, Vasquez L, Iyo F, Abengoechea S. Photodynamic therapy in the management of circumscribed choroidal hemangioma. Can J Ophthalmol 2012;47:16–20.
19. Jurklies B, Anastassiou G, Ortmans S, Schüler A, Schilling H, Schmidt-Erfurth U, et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003;87:84–89.
20. Madreperla SA. Choroidal hemangioma treated with photodynamic therapy using verteporfin. Arch Ophthalmol 2001;119:1606–1610.
21. Chargari C, Deutsch E, Blanchard P, Gouy S, Martelli H, Guérin F, et al. Brachytherapy: An overview for clinicians. CA Cancer J Clin 2019;69:386–401.
22. Naseripour M, Maleki A, Astaraki A, Sedaghat A, Jaberi R, Lee S, et al. Ruthenium-106 brachytherapy in the treatment of circumscribed choroidal hemangioma. Retina 2018;38:1024–1030.
23. Muniruzzaman M, Mardirossian G, Fuller D, Giap H. SUGG- T-150: Accelerated partial breast robotic IMRT with CyberKnife: Case study and clinical experience. Med Phys 2010;37:3219.
24. Ta M, Jones L, Frantzis J, Sisson T, Middleton M. The potential use of intensity-modulated radiation therapy in the management of early-stage gynaecologic malignancies. Radiographer 2008;55:22–27.
